Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Conjugated Secondary Antibodies

By Drug Discovery Trends Editor | November 4, 2013

Abcam's new Alexa Fluor 405/568/750 conjugated secondary antibodies to its existing Alexa Fluor 488/555/594/647 conjugates. (Source: Abcam)Abcam’s new Alexa Fluor 405/568/750 conjugated secondary antibodies to its existing Alexa Fluor 488/555/594/647 conjugates. Extensively tested in Abcam’s labs, the Alexa Fluor range guarantees bright staining and low background. The different color variants were selected to provide an increased selection for multicolor staining.
 
The Alexa Fluor portfolio comprises antibodies raised against  mouse/rabbit/rat/chicken/goat/sheep/guinea-pig IgG and against mouse/rabbit IgM. It also includes a large selection of pre-adsorbed/cross-adsorbed and F(ab’)2 fragment secondaries to ensure low species cross-reactivity. A dilution range of 1/200 -1/1000 in IF/ICC allows for at least 250 stainings per product to improve cost efficiency.
 
Abcam Alexa Fluor secondaries are designed for cell biologists and microscopists undertaking multicolor staining from all research backgrounds. The addition of these products complements Abcam’s innovative RabMAb rabbit monoclonal antibodies products.
 
Abcam Alexa Fluor secondaries are accompanied with information-rich datasheets, fast delivery, and expert scientific support. They are available globally and can be purchased directly through the Abcam website or through one of Abcam’s authorised distributors. 
 
Date: November 4, 2013
Source: Abcam plc  

Filed Under: Drug Discovery

 

Related Articles Read More >

FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE